On January 2, Gelonghui reported that KPC Pharmaceuticals, Inc. (600422.SH) announced that on December 30, 2024, the company and its subsidiaries participated in the centralized procurement organized by the National Chinese Patent Medicine Joint Procurement Office (hereinafter referred to as "Joint Procurement Office") for the national Chinese Patent Medicine procurement alliance (the first batch of expansion continuation). According to the "Public Announcement of the Proposed Selected Results for Centralized Volume Procurement by the National Chinese Patent Medicine Procurement Alliance" released by the Joint Procurement Office, products such as the company's injectable Xuesaitong (freeze-dried), Xuesaitong Pharmaceutical Co., Ltd. (hereinafter referred to as "Xuesaitong Pharmaceutical"), Xuesaitong droplet pills, and Kunming China Resources Shenghuo Pharmaceutical Co., Ltd. (hereinafter referred to as "Shenghuo Pharmaceutical") Xuesaitong soft capsules are proposed for selection in this centralized procurement.
昆药集团(600422.SH)：参加全国中成药采购联盟集中采购拟中选
KPC Pharmaceuticals, Inc. (600422.SH): Participating in the centralized procurement of the National Chinese Patent Medicine Purchasing Alliance is expected to be selected.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated